Drugs / FN-1501
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03690154 | Jul 2018 → Feb 2022 | acute myeloid leukemia | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2019-11-30 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Regulatory Fosun Pharma’s New Development Leukemia Drug FN-1501 Receives FDA Orphan Drug Designation fosunpharma.com ↗
has received the U.S. Food and Drug Administration (the “FDA”)’s Orphan Drug Designation for its investigational drug FN-1501. |
| 2018-01-16 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Regulatory Fosun Pharma Receives China Food and Drug Administration Approval for Clinical Trials of New Medicine for Treatment of Leukemia fosunpharma.com ↗ |
| 2017-10-29 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Regulatory Fosun Pharma Drug for Treatment of Leukaemia Gets US FDA Approval for Clinical Trials fosunpharma.com ↗
Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. received a letter from the US Food and Drug Administration (referred to as "US FDA") agreeing to clinical trials for the new drug FN-1501 used for treatment of leukaemia. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-11-30 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Fosun Pharma’s New Development Leukemia Drug FN-1501 Receives FDA Orphan Drug Designation fosunpharma.com ↗ |
| 2018-01-16 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Fosun Pharma Receives China Food and Drug Administration Approval for Clinical Trials of New Medicine for Treatment of Leukemia fosunpharma.com ↗ |
| 2017-10-29 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Fosun Pharma Drug for Treatment of Leukaemia Gets US FDA Approval for Clinical Trials fosunpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FN-1501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03690154 ↗ |
| Route | Intravenous | “Eligible patients will receive a single intravenous infusion of study drug on Days 1, 3, 5, 8, 10, and 12 of a 21-day cycle.” NCT03690154 ↗ |